glp 1 in obesity The activity of GLP-1 and GIP for Type 2 Diabetes and GLP-1 for Weight Loss and

The current understanding of pharmacotherapy in BED, however, remains limited due to gaps and methodological limitations in the literature [4]

Currently, semaglutide is the best characterized GLP-1 RA in the context of overweight/obesity, CVD risk and kidney disease, but the clinical development program for tirzepatide is expected to be completed with CVD information and preliminary kidney disease results in the next 3 years

W., Abdulelah, A

Wang, B

[DOI] [PMC free article] [PubMed] [Google Scholar] 181.De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L

Nat Med 29(12):29932995